Edgewise Therapeutics, Inc. (EWTX) Stock
4 of the hedge funds AlphaScala tracks reported EWTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $19.08M. Company insiders reported 0 open-market buys and 19 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own EWTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 470K | $19.08M | +9% |
| D.E. Shaw David Shaw | 189K | $7.68M | +80% |
| Point72 Steve Cohen | 117K | $4.76M | NEW |
| Marshall Wace | 6K | $247.8K | -99% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Edgewise Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 13, 26 | Donovan Joanne M. | CMO | SELL | 2.9K | $127K |
| Aug 12, 26 | Koch Kevin | President and CEO | SELL | 8.8K | $383K |
| Aug 12, 26 | Koch Kevin | President and CEO | SELL | 8.3K | $361K |
| Aug 12, 26 | Koch Kevin | President and CEO | SELL | 913 | $40K |
| Aug 12, 26 | Moore John R | General Counsel | SELL | 2.4K | $107K |
| Aug 12, 26 | Moore John R | General Counsel | SELL | 59 | $3K |
| Aug 12, 26 | Moore John R | General Counsel | SELL | 99 | $4K |
| Aug 12, 26 | Moore John R | General Counsel | SELL | 2.4K | $106K |
| Aug 12, 26 | Donovan Joanne M. | CMO | SELL | 2.8K | $124K |
| Aug 12, 26 | Donovan Joanne M. | CMO | SELL | 2.8K | $121K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →EWTX price chart
Powered by TradingViewWhat does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders. The company's primary function is to address unmet medical needs in the area of muscular health, specifically aiming to develop treatments for conditions such as Duchenne muscular dystrophy. Edgewise Therapeutics employs a cutting-edge approach by utilizing small molecule drugs to modulate proteins critical to muscle function and health. Operating within the biopharmaceutical industry, Edgewise is part of a niche sector where advancements can lead to significant improvements in patient care. Their efforts contribute to the broader medical and pharmaceutical markets by potentially offering new therapeutic options that can have a profound impact on patients' lives. Market significance is underscored by the ongoing need for effective treatments for rare diseases, which often lack adequate therapeutic solutions. Edgewise Therapeutics is an example of how specialized research and development can drive innovation in healthcare, seeking to transform scientific advancements into life-changing medications.